Skip to Main Content
Table 1.

Patient baseline characteristics

CharacteristicN = 25
Age, median (range), years 53.0 (36–79) 
Female, n (%) 25 (100) 
Race, n (%) 
 White 16 (64) 
 Asian 4 (16) 
 Black or African American 1 (4) 
 Not specified 4 (16) 
ECOG performance status, n (%) 
 0 13 (52) 
 1 11 (44) 
 Unknown 1 (4) 
Histology, n (%) 
 Ductal carcinoma 13 (52) 
 Adenocarcinoma (NOS) 6 (24) 
 Lobular carcinoma 3 (12) 
 Carcinoid 2 (8) 
 Neuroendocrine 1 (4) 
LDH level, n (%) 
 Normal 11 (44) 
 Elevated 11 (44) 
 Null 3 (12) 
Prior (neo)adjuvant therapy, n (%) 17 (68) 
Prior systemic therapies for metastatic disease, n (%) 
 0 2 (8) 
 1 1 (4) 
 2 2 (8) 
 3 4 (16) 
 4 4 (16) 
 ≥5 12 (48) 
Type of prior therapy, n (%)a,b 
 Chemotherapy 25 (100) 
 Endocrine therapy 22 (88) 
  Tamoxifen 19 (76) 
  Fulvestrant 9 (36) 
  Aromatase inhibitor 17 (68) 
 Other investigational therapy 7 (28) 
CharacteristicN = 25
Age, median (range), years 53.0 (36–79) 
Female, n (%) 25 (100) 
Race, n (%) 
 White 16 (64) 
 Asian 4 (16) 
 Black or African American 1 (4) 
 Not specified 4 (16) 
ECOG performance status, n (%) 
 0 13 (52) 
 1 11 (44) 
 Unknown 1 (4) 
Histology, n (%) 
 Ductal carcinoma 13 (52) 
 Adenocarcinoma (NOS) 6 (24) 
 Lobular carcinoma 3 (12) 
 Carcinoid 2 (8) 
 Neuroendocrine 1 (4) 
LDH level, n (%) 
 Normal 11 (44) 
 Elevated 11 (44) 
 Null 3 (12) 
Prior (neo)adjuvant therapy, n (%) 17 (68) 
Prior systemic therapies for metastatic disease, n (%) 
 0 2 (8) 
 1 1 (4) 
 2 2 (8) 
 3 4 (16) 
 4 4 (16) 
 ≥5 12 (48) 
Type of prior therapy, n (%)a,b 
 Chemotherapy 25 (100) 
 Endocrine therapy 22 (88) 
  Tamoxifen 19 (76) 
  Fulvestrant 9 (36) 
  Aromatase inhibitor 17 (68) 
 Other investigational therapy 7 (28) 

Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; NOS, not otherwise specified.

aPatients could have received ≥1 type of prior therapy.

bNot all prior therapies are listed.

Close Modal

or Create an Account

Close Modal
Close Modal